RACC Files S-4 for Oak Hill Bio Merger: $55M PIPE, $75M Backstop, 42.4% Target Ownership
RACC has more than doubled off its 52-week low of $10.21 on elevated volume (2.3× avg).
Summary
RACC's S-4 details its merger with Oak Hill Bio: $160M base equity value, $55M PIPE, $75M redemption backstop, and significant dilution for public shareholders from 82.4% to 22.6% ownership.
Key Events · M&A and Partnerships · RACC
-
Oak Hill Bio Merger Terms Finalized
RACC will acquire 100% of Oak Hill Bio for $160M base equity value plus $45M SAFE amount, paid in New OHB Common Stock at $10.00/share. Oak Hill Bio shareholders will own 42.4% of the combined company.
-
PIPE Financing Reduced to $55M
The PIPE was finalized at $55M (5.5M shares at $10.00), down from the $100M initially reported on July 27. Existing RACC shareholders subscribed for $21.8M, existing Oak Hill Bio shareholders $8.8M, and crossover investors $22.5M.
-
$75M Redemption Backstop
RA Capital Healthcare Fund, a sponsor affiliate, committed up to $75M (7.5M shares at $10.00) to backstop public shareholder redemptions, ensuring the combined company receives at least $75M from the trust account regardless of redemption levels.
-
Public Shareholder Dilution
Public shareholders currently own 82.4% of RACC but will hold only 22.6% of New Oak Hill Bio if no redemptions occur. Sponsor founder shares cost $0.02/share versus $10.00 for public investors.
Analysis · RACC · Real Estate & Construction
The S-4 registration statement finalizes the terms of RACC's acquisition of Oak Hill Bio, a clinical-stage biotech developing rugonersen for Angelman syndrome. The deal values Oak Hill Bio at $160M base equity, with a $55M PIPE at $10.00/share and a $75M backstop from sponsor affiliate RA Capital to cover redemptions. Public shareholders face immediate dilution — they currently own 82.4% of RACC but will hold only 22.6% of the combined company if no redemptions occur. The sponsor's founder shares cost $0.02/share versus $10.00 for public investors, creating a significant incentive misalignment. The filing also discloses Oak Hill Bio's material weaknesses in internal controls and going concern risk, consistent with RACC's own Q2 10-Q disclosures.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RACC was trading at $21.05 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $191.5M. The 52-week trading range was $10.21 to $33.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.